secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2024-10-21T23:59:59+00:00
Accession:  0001213900-24-089095
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna Therapeutics appoints cell therapy veteran Mert Aktar to board
----------------------------------------------------------------------

- Appointed Mert Aktar as Class III director, effective Oct 20, 2024; joins Audit and Science & Technology Committees.
- Aktar currently CEO of Receptive Bio; previously SVP Global Head of Corp Dev at Kite Pharma; over 20 years biopharma experience.
- As non-employee director, receives $40k/yr cash, $10k Audit, $7.5k SciTech committee fees; plus $350k option grant vesting monthly over 3 years.
- Appointment adds cell therapy and corporate development expertise as Kyverna advances KYV-101 in autoimmune disease trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000121390024089095/0001213900-24-089095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000121390024089095/ea0218096-8k_kyverna.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-089095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer